FDA Approves Pharming’s Joenja as First Treatment for Children with APDS in the U.S.
RegulatoryapprovedJoenjaPositive
AI Analysis
Summary
Pharming announced FDA approval of Joenja (generic name not specified) as the first treatment for children with APDS in the United States, addressing a rare immune and genetic disorder.
Outcome Details
FDA approval for first treatment for children with APDS in the U.S.
Importance:9/10
Sentiment:
0.95
FDA approvalrare diseasepediatric indicationfirst-in-classimmune diseasegenetic disease
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 11, 2026 10:09 PM